NCT03983226View on ClinicalTrials.gov

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

PHASE2RecruitingINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
Ovarian Cancer RecurrentFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
PROCEDURE

Surgery

Tumor debulking surgery (surgery in recurrent ovarian disease)

DRUG

carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...

Salvage chemotherapy

DRUG

Niraparib

Niraparib maintenance therapy

Trial Locations (5)

200032

RECRUITING

Fudan University Shanghai Zhongshan Hospital, Shanghai

Unknown

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

NOT_YET_RECRUITING

Fudan University, Shanghai

NOT_YET_RECRUITING

Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Shanghai Gynecologic Oncology Group

OTHER_GOV